Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955269932> ?p ?o ?g. }
- W2955269932 endingPage "246" @default.
- W2955269932 startingPage "232" @default.
- W2955269932 abstract "Immune checkpoint blockade therapies (ICBs) are a prominent breakthrough in cancer immunotherapy in recent years (named the 2013 Breakthrough of the Year by the Science magazine). Thus far, FDA-approved ICBs primarily target immune checkpoints CTLA-4, PD-1, and PD-L1. Notwithstanding their impressive long-term therapeutic benefits, their efficacy is limited to a small subset of cancer patients. In addition, ICBs induce inadvertent immune-related adverse events (irAEs) and can be costly for long-term use. To overcome these limitations, two strategies are actively being pursued: identification of predictive biomarkers for clinical response to ICBs and multi-pronged combination therapies. Biomarkers will allow clinicians to practice a precision medicine approach in ICBs (biomarker-based patient selection) such as treating triple-negative breast cancer patients that exhibit PD-L1 staining of tumor-infiltrating immune cells in ≥1% of the tumor area with nanoparticle albumin-bound (nab)-paclitaxel plus anti-PD-L1 and treating patients of MSI-H or MMR deficient unresectable or metastatic solid tumors with pembrolizumab (anti-PD-1). Importantly, the insights gained from these biomarker studies can guide rational combinatorial strategies such as CDK4/6 inhibitor/fractionated radiotherapy/HDACi in conjunction with ICBs to maximize therapeutic benefits. Further, with the rapid technological advents (e.g., ATCT-Seq), we predict more reliable biomarkers will be identified, which in turn will inspire more promising combination therapies." @default.
- W2955269932 created "2019-07-12" @default.
- W2955269932 creator A5007095838 @default.
- W2955269932 creator A5013854802 @default.
- W2955269932 creator A5035724058 @default.
- W2955269932 creator A5050266184 @default.
- W2955269932 creator A5051187652 @default.
- W2955269932 creator A5072016490 @default.
- W2955269932 creator A5091161682 @default.
- W2955269932 date "2019-09-01" @default.
- W2955269932 modified "2023-09-26" @default.
- W2955269932 title "Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies" @default.
- W2955269932 cites W1498931318 @default.
- W2955269932 cites W1580205301 @default.
- W2955269932 cites W1905278501 @default.
- W2955269932 cites W1910012553 @default.
- W2955269932 cites W1940241680 @default.
- W2955269932 cites W1964080141 @default.
- W2955269932 cites W1967889234 @default.
- W2955269932 cites W1971208896 @default.
- W2955269932 cites W1973769650 @default.
- W2955269932 cites W1974885520 @default.
- W2955269932 cites W1982488143 @default.
- W2955269932 cites W1984642649 @default.
- W2955269932 cites W1994993231 @default.
- W2955269932 cites W2004630197 @default.
- W2955269932 cites W2011088911 @default.
- W2955269932 cites W2011458181 @default.
- W2955269932 cites W2012694594 @default.
- W2955269932 cites W2013020286 @default.
- W2955269932 cites W2014396605 @default.
- W2955269932 cites W2016983859 @default.
- W2955269932 cites W2021472146 @default.
- W2955269932 cites W2026318599 @default.
- W2955269932 cites W2028433016 @default.
- W2955269932 cites W2032166347 @default.
- W2955269932 cites W2039123767 @default.
- W2955269932 cites W2042470707 @default.
- W2955269932 cites W2042687451 @default.
- W2955269932 cites W2046972425 @default.
- W2955269932 cites W2049553585 @default.
- W2955269932 cites W2049601932 @default.
- W2955269932 cites W2050302632 @default.
- W2955269932 cites W2050457398 @default.
- W2955269932 cites W2057893793 @default.
- W2955269932 cites W2063384194 @default.
- W2955269932 cites W2063888187 @default.
- W2955269932 cites W2066671159 @default.
- W2955269932 cites W2072451938 @default.
- W2955269932 cites W2076948707 @default.
- W2955269932 cites W2076956606 @default.
- W2955269932 cites W2079018735 @default.
- W2955269932 cites W2079315541 @default.
- W2955269932 cites W2094366129 @default.
- W2955269932 cites W2097995306 @default.
- W2955269932 cites W2099023072 @default.
- W2955269932 cites W2099842815 @default.
- W2955269932 cites W2103021272 @default.
- W2955269932 cites W2103277177 @default.
- W2955269932 cites W2103876938 @default.
- W2955269932 cites W2104347254 @default.
- W2955269932 cites W2104885590 @default.
- W2955269932 cites W2107408397 @default.
- W2955269932 cites W2107429737 @default.
- W2955269932 cites W2108789863 @default.
- W2955269932 cites W2109485845 @default.
- W2955269932 cites W2112601576 @default.
- W2955269932 cites W2118471749 @default.
- W2955269932 cites W2123363005 @default.
- W2955269932 cites W2124427232 @default.
- W2955269932 cites W2125616358 @default.
- W2955269932 cites W2127733313 @default.
- W2955269932 cites W2128035403 @default.
- W2955269932 cites W2128758225 @default.
- W2955269932 cites W2129482327 @default.
- W2955269932 cites W2132564070 @default.
- W2955269932 cites W2137695731 @default.
- W2955269932 cites W2142300779 @default.
- W2955269932 cites W2143163879 @default.
- W2955269932 cites W2145989336 @default.
- W2955269932 cites W2146791037 @default.
- W2955269932 cites W2148785961 @default.
- W2955269932 cites W2149360266 @default.
- W2955269932 cites W2149642154 @default.
- W2955269932 cites W2153162429 @default.
- W2955269932 cites W2156353875 @default.
- W2955269932 cites W2160834915 @default.
- W2955269932 cites W2164221986 @default.
- W2955269932 cites W2165456770 @default.
- W2955269932 cites W2166662937 @default.
- W2955269932 cites W2171365282 @default.
- W2955269932 cites W2176126538 @default.
- W2955269932 cites W2185075416 @default.
- W2955269932 cites W2199397492 @default.
- W2955269932 cites W2201379305 @default.
- W2955269932 cites W2253000935 @default.
- W2955269932 cites W2267367070 @default.
- W2955269932 cites W2282550179 @default.